Crinetics Pharmaceuticals, Inc. (CRNX) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, Crinetics Pharmaceuticals, Inc.'s filing signal turned positive.

Crinetics Pharmaceuticals is a commercial-stage pharmaceutical company focused on transforming the treatment of endocrine diseases and endocrine-related tumors by developing novel small molecule therapies targeting G protein-coupled receptors (GPCRs). The company's lead product, PALSONIFYTM (paltusotine), received FDA approval in September 2025 as the first once-daily, oral treatment for acromegaly in adults with an inadequate response to surgery or for whom surgery is not an option. Paltusotine is also in clinical development for carcinoid syndrome associated with neuroendocrine tumors. Crinetics has a pipeline of over 10 programs, including late-stage candidate atumelnant for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome, and CRN09682, a nonpeptide drug conjugate for SST2-expressing tumors. The company's strategy centers on commercializing its approved product, advancing its pipeline through clinical development, and expanding its therapeutic focus within endocrinology.

Revenue is primarily driven by product sales of PALSONIFY in the U.S. and collaboration and license revenue from partnerships, such as the agreement with SKK for the commercialization of paltusotine in Japan.